Everything we've seen

1. ·Sep 14, 2:49 PMstreamnews

   Tracking Ron Baron's BAMCO Portfolio - Q2 2026 Update

   Ron Baron’s BAMCO 13F hits $66.6B, led by SpaceX, Tesla & MSCI.

2. ·Sep 14, 2:34 PMstreamnews

   Tracking Ron Baron's BAMCO Portfolio - Q2 2026 Update

   Ron Baron’s BAMCO 13F hits $66.6B, led by SpaceX, Tesla & MSCI.

3. ?Sep 14, 2:20 PMdecisionconsidered

   Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

   IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

4. !Sep 14, 2:20 PMsignalseverity 0.19

   Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

   IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

5. ·Sep 14, 1:34 PMstreamnews

   IDEXX Laboratories, Inc. (IDXX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

   IDEXX Laboratories, Inc. (IDXX) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 10:45 AM EDTCompany ParticipantsMichael Erickson...

6. ?Sep 14, 1:20 PMdecisionconsidered

   Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

   IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

7. !Sep 14, 1:20 PMsignalseverity 0.19

   Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

   IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

8. ?Sep 14, 12:20 PMdecisionconsidered

   Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

   IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

9. !Sep 14, 12:20 PMsignalseverity 0.19

   Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

   IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

10. ✓Sep 14, 11:21 AMdecisionacted

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] IDXX is down 13.4% from its 30-day high with no headline news, no insider selling, no fundamental deterioration visible in the sparse 10-Q/8-K filings, and no imminent earnings (61 days away). The Health Care sector ranks 2nd of 11 by 30-day relative strength with strong +5.32pt outperformance vs. SPY, suggesting the drop is somewhat idiosyncratic to IDXX rather than sector-wide. Options flow is modestly bullish with a P/C ratio of 0.88 and call volume slightly exceeding puts, though z-scores are unavailable. Net signal score is approximately 0 to +1: positives include clean earnings runway (+1) and neutral-to-improving macro/VIX at 30th percentile (+1); negatives include idiosyncratic drop in an outperforming sector (-1) and high 10Y yield at 4.75% which is a headwind for a premium-valued growth name like IDXX (-1). Anchoring at the ~55% base rate for a sound large-cap dip and adjusting marginally downward for idiosyncratic ris

11. ?Sep 14, 11:21 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

12. !Sep 14, 11:21 AMsignalseverity 0.19

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

13. ?Sep 14, 10:21 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

14. !Sep 14, 10:21 AMsignalseverity 0.19

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

15. ?Sep 14, 10:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] IDXX is down 13.4% from its 30-day high with no headline news, no insider selling, no fundamental deterioration visible in the sparse 10-Q/8-K filings, and no imminent earnings (61 days away). The Health Care sector ranks 2nd of 11 by 30-day relative strength with strong +5.32pt outperformance vs. SPY, suggesting the drop is somewhat idiosyncratic to IDXX rather than sector-wide. Options flow is modestly bullish with a P/C ratio of 0.88 and call volume slightly exceeding puts, though z-scores are unavailable. Net signal score is approximately 0 to +1: positives include clean earnings runway (+1) and neutral-to-improving macro/VIX at 30th percentile (+1); negatives include idiosyncratic drop in an outperforming sector (-1) and high 10Y yield at 4.75% which is a headwind for a premium-valued growth name like IDXX (-1). Anchoring at the ~55% base rate for a sound large-cap dip and adjusting marginally downward for idiosyncratic ris

16. ❖Sep 14, 9:01 AMnewsvia finnhub

    IDEXX Laboratories, Inc. (IDXX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

    IDEXX Laboratories, Inc. (IDXX) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 10:45 AM EDTCompany ParticipantsMichael Erickson...

17. ?Sep 14, 7:01 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] IDXX is down 13.4% from its 30-day high with no headline news, no insider selling, no fundamental deterioration visible in the sparse 10-Q/8-K filings, and no imminent earnings (61 days away). The Health Care sector ranks 2nd of 11 by 30-day relative strength with strong +5.32pt outperformance vs. SPY, suggesting the drop is somewhat idiosyncratic to IDXX rather than sector-wide. Options flow is modestly bullish with a P/C ratio of 0.88 and call volume slightly exceeding puts, though z-scores are unavailable. Net signal score is approximately 0 to +1: positives include clean earnings runway (+1) and neutral-to-improving macro/VIX at 30th percentile (+1); negatives include idiosyncratic drop in an outperforming sector (-1) and high 10Y yield at 4.75% which is a headwind for a premium-valued growth name like IDXX (-1). Anchoring at the ~55% base rate for a sound large-cap dip and adjusting marginally downward for idiosyncratic risk and rate headwinds yields a modest bu

18. ?Sep 14, 7:00 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

19. !Sep 14, 7:00 AMsignalseverity 0.19

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

20. ❖Sep 13, 12:42 PMnewsvia finnhub

    Tracking Ron Baron's BAMCO Portfolio - Q2 2026 Update

    Ron Baron’s BAMCO 13F hits $66.6B, led by SpaceX, Tesla & MSCI.

21. ?Sep 11, 6:04 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    IDXX (IDEXX Laboratories) is a fundamentally strong, high-quality compounder in veterinary diagnostics with durable recurring revenue and strong market positioning — no company-specific bad news, guidance cuts, or accounting issues are evident in the available filings or news. The 19.1% drawdown from the 30-day high appears macro-driven rather than fundamental: the 5-year forward inflation expectation (T5YIFR) is running 1.8σ above trend, which pressures rate-sensitive and high-multiple growth stocks like IDXX. However, the absence of any news headlines and sparse 10-Q metrics make it difficult to confirm near-term earnings trajectory, and elevated inflation expectations could sustain multiple compression pressure over the 90-day horizon.

22. !Sep 11, 6:04 PMsignalseverity 0.19

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    IDXX (IDEXX Laboratories) is a fundamentally strong, high-quality compounder in veterinary diagnostics with durable recurring revenue and strong market positioning — no company-specific bad news, guidance cuts, or accounting issues are evident in the available filings or news. The 19.1% drawdown from the 30-day high appears macro-driven rather than fundamental: the 5-year forward inflation expectation (T5YIFR) is running 1.8σ above trend, which pressures rate-sensitive and high-multiple growth stocks like IDXX. However, the absence of any news headlines and sparse 10-Q metrics make it difficult to confirm near-term earnings trajectory, and elevated inflation expectations could sustain multiple compression pressure over the 90-day horizon.

23. ?Sep 11, 6:00 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 4: close $504.70 < MA150 $571.35 (-11.7%), MA falling, 34.5% off 52w high, vol 0.79× avg

24. ?Sep 11, 4:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] IDXX is down 13.4% from its 30-day high with no headline news, no insider selling, no fundamental deterioration visible in the sparse 10-Q/8-K filings, and no imminent earnings (61 days away). The Health Care sector ranks 2nd of 11 by 30-day relative strength with strong +5.32pt outperformance vs. SPY, suggesting the drop is somewhat idiosyncratic to IDXX rather than sector-wide. Options flow is modestly bullish with a P/C ratio of 0.88 and call volume slightly exceeding puts, though z-scores are unavailable. Net signal score is approximately 0 to +1: positives include clean earnings runway (+1) and neutral-to-improving macro/VIX at 30th percentile (+1); negatives include idiosyncratic drop in an outperforming sector (-1) and high 10Y yield at 4.75% which is a headwind for a premium-valued growth name like IDXX (-1). Anchoring at the ~55% base rate for a sound large-cap dip and adjusting marginally downward for idiosyncratic risk and rate headwinds yields a modest buy signal.

25. ?Sep 11, 4:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

26. !Sep 11, 4:20 PMsignalseverity 0.19

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

27. ?Sep 11, 3:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

28. !Sep 11, 3:20 PMsignalseverity 0.20

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

29. ?Sep 11, 3:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] IDXX is down 13.4% from its 30-day high with no headline news, no insider selling, no fundamental deterioration visible in the sparse 10-Q/8-K filings, and no imminent earnings (61 days away). The Health Care sector ranks 2nd of 11 by 30-day relative strength with strong +5.32pt outperformance vs. SPY, suggesting the drop is somewhat idiosyncratic to IDXX rather than sector-wide. Options flow is modestly bullish with a P/C ratio of 0.88 and call volume slightly exceeding puts, though z-scores are unavailable. Net signal score is approximately 0 to +1: positives include clean earnings runway (+1) and neutral-to-improving macro/VIX at 30th percentile (+1); negatives include idiosyncratic drop in an outperforming sector (-1) and high 10Y yield at 4.75% which is a headwind for a premium-valued growth name like IDXX (-1). Anchoring at the ~55% base rate for a sound large-cap dip and adjusting marginally downward for idiosyncratic risk and rate headwinds yields a modest buy signal.

30. ?Sep 11, 2:21 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

31. !Sep 11, 2:21 PMsignalseverity 0.19

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

32. ?Sep 11, 2:21 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] IDXX is down 13.4% from its 30-day high with no headline news, no insider selling, no fundamental deterioration visible in the sparse 10-Q/8-K filings, and no imminent earnings (61 days away). The Health Care sector ranks 2nd of 11 by 30-day relative strength with strong +5.32pt outperformance vs. SPY, suggesting the drop is somewhat idiosyncratic to IDXX rather than sector-wide. Options flow is modestly bullish with a P/C ratio of 0.88 and call volume slightly exceeding puts, though z-scores are unavailable. Net signal score is approximately 0 to +1: positives include clean earnings runway (+1) and neutral-to-improving macro/VIX at 30th percentile (+1); negatives include idiosyncratic drop in an outperforming sector (-1) and high 10Y yield at 4.75% which is a headwind for a premium-valued growth name like IDXX (-1). Anchoring at the ~55% base rate for a sound large-cap dip and adjusting marginally downward for idiosyncratic risk and rate headwinds yields a modest buy signal.

33. ?Sep 11, 1:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

34. !Sep 11, 1:20 PMsignalseverity 0.19

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

35. ?Sep 11, 1:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] IDXX is down 13.4% from its 30-day high with no headline news, no insider selling, no fundamental deterioration visible in the sparse 10-Q/8-K filings, and no imminent earnings (61 days away). The Health Care sector ranks 2nd of 11 by 30-day relative strength with strong +5.32pt outperformance vs. SPY, suggesting the drop is somewhat idiosyncratic to IDXX rather than sector-wide. Options flow is modestly bullish with a P/C ratio of 0.88 and call volume slightly exceeding puts, though z-scores are unavailable. Net signal score is approximately 0 to +1: positives include clean earnings runway (+1) and neutral-to-improving macro/VIX at 30th percentile (+1); negatives include idiosyncratic drop in an outperforming sector (-1) and high 10Y yield at 4.75% which is a headwind for a premium-valued growth name like IDXX (-1). Anchoring at the ~55% base rate for a sound large-cap dip and adjusting marginally downward for idiosyncratic risk and rate headwinds yields a modest buy signal.

36. ?Sep 11, 12:21 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

37. !Sep 11, 12:21 PMsignalseverity 0.19

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

38. ?Sep 11, 12:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] IDXX is down 13.4% from its 30-day high with no headline news, no insider selling, no fundamental deterioration visible in the sparse 10-Q/8-K filings, and no imminent earnings (61 days away). The Health Care sector ranks 2nd of 11 by 30-day relative strength with strong +5.32pt outperformance vs. SPY, suggesting the drop is somewhat idiosyncratic to IDXX rather than sector-wide. Options flow is modestly bullish with a P/C ratio of 0.88 and call volume slightly exceeding puts, though z-scores are unavailable. Net signal score is approximately 0 to +1: positives include clean earnings runway (+1) and neutral-to-improving macro/VIX at 30th percentile (+1); negatives include idiosyncratic drop in an outperforming sector (-1) and high 10Y yield at 4.75% which is a headwind for a premium-valued growth name like IDXX (-1). Anchoring at the ~55% base rate for a sound large-cap dip and adjusting marginally downward for idiosyncratic risk and rate headwinds yields a modest buy signal.

39. ?Sep 10, 4:26 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] IDXX is down 13.4% from its 30-day high with no headline news, no insider selling, no fundamental deterioration visible in the sparse 10-Q/8-K filings, and no imminent earnings (61 days away). The Health Care sector ranks 2nd of 11 by 30-day relative strength with strong +5.32pt outperformance vs. SPY, suggesting the drop is somewhat idiosyncratic to IDXX rather than sector-wide. Options flow is modestly bullish with a P/C ratio of 0.88 and call volume slightly exceeding puts, though z-scores are unavailable. Net signal score is approximately 0 to +1: positives include clean earnings runway (+1) and neutral-to-improving macro/VIX at 30th percentile (+1); negatives include idiosyncratic drop in an outperforming sector (-1) and high 10Y yield at 4.75% which is a headwind for a premium-valued growth name like IDXX (-1). Anchoring at the ~55% base rate for a sound large-cap dip and adjusting marginally downward for idiosyncratic risk and rate headwinds yields a modest buy signal.

40. ?Sep 10, 4:26 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

41. !Sep 10, 4:26 PMsignalseverity 0.19

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

42. ❖Sep 10, 1:05 PMnewsvia finnhub

    Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For?

    If you hold Pfizer (PFE) or Zoetis (ZTS), you hold the same idea: a branded medicine becomes a standard of care and keeps earning for years, in people or in animals. That is where it stops. Pfizer is buying replacements for older drugs losing exclusivity. Zoetis is cutting its effective price to keep the franchises it has. Same bet, two opposite defenses.

43. ❖Sep 10, 7:20 AMnewsvia finnhub

    Insider Alert: IDEXX Director Lawrence Kingsley Sells $1.2 Million of Stock

    Kingsley exercised options at $114.17 per share before immediately selling at $532.08, capturing a significant gain. His direct stake remains at 9,568 shares worth $5.12 million.

44. ❖Sep 10, 7:01 AMnewsvia finnhub

    Engaging In Options Activity, Lawrence D Kingsley Exercises Options Valued At $873K In IDEXX Laboratories

    In a new SEC filing on September 9, it was revealed that Kingsley, Board Member at IDEXX Laboratories (NASDAQ:IDXX), executed a significant exercise of company stock options. What Happened: Disclosed in a Form 4 filing

45. ❖Sep 10, 6:15 AMnewsvia finnhub

    Baron Partners Fund Q2 2026 Contributors And Detractors

    Top contributors include Space Exploration Technologies, Tesla, Red Rock Resorts, Hyatt Hotels and Birkenstock Holding. Read more here.

46. ❖Sep 10, 5:21 AMnewsvia finnhub

    Is IDEXX Laboratories Stock Underperforming the Dow?

    Despite trailing the Dow over the past year, IDEXX still has Wall Street on its side, with analysts maintaining a cautiously optimistic view on its future prospects.

47. ▣Sep 9, 8:00 PMjournalstop

    Agent 4 — Dip Buyer (Frozen) closed long 1 @ $506.49 (-$46.95)

    intraday stop sweep

48. ?Sep 9, 4:25 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

49. !Sep 9, 4:25 PMsignalseverity 0.17

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

50. ?Sep 9, 4:25 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] IDXX is down 13.4% from its 30-day high with no headline news, no insider selling, no fundamental deterioration visible in the sparse 10-Q/8-K filings, and no imminent earnings (61 days away). The Health Care sector ranks 2nd of 11 by 30-day relative strength with strong +5.32pt outperformance vs. SPY, suggesting the drop is somewhat idiosyncratic to IDXX rather than sector-wide. Options flow is modestly bullish with a P/C ratio of 0.88 and call volume slightly exceeding puts, though z-scores are unavailable. Net signal score is approximately 0 to +1: positives include clean earnings runway (+1) and neutral-to-improving macro/VIX at 30th percentile (+1); negatives include idiosyncratic drop in an outperforming sector (-1) and high 10Y yield at 4.75% which is a headwind for a premium-valued growth name like IDXX (-1). Anchoring at the ~55% base rate for a sound large-cap dip and adjusting marginally downward for idiosyncratic risk and rate headwinds yields a modest buy signal.

51. ?Sep 8, 6:03 PMdecisionconsidered

    Agent 2 — Adaptive — considered

    Stage 4: close $520.21 < MA150 $573.97 (-9.4%), MA falling, 32.4% off 52w high, vol 1.22× avg

52. ?Sep 8, 4:22 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] IDXX is down 13.4% from its 30-day high with no headline news, no insider selling, no fundamental deterioration visible in the sparse 10-Q/8-K filings, and no imminent earnings (61 days away). The Health Care sector ranks 2nd of 11 by 30-day relative strength with strong +5.32pt outperformance vs. SPY, suggesting the drop is somewhat idiosyncratic to IDXX rather than sector-wide. Options flow is modestly bullish with a P/C ratio of 0.88 and call volume slightly exceeding puts, though z-scores are unavailable. Net signal score is approximately 0 to +1: positives include clean earnings runway (+1) and neutral-to-improving macro/VIX at 30th percentile (+1); negatives include idiosyncratic drop in an outperforming sector (-1) and high 10Y yield at 4.75% which is a headwind for a premium-valued growth name like IDXX (-1). Anchoring at the ~55% base rate for a sound large-cap dip and adjusting marginally downward for idiosyncratic risk and rate headwinds yields a modest buy signal.

53. ?Sep 8, 4:22 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

54. !Sep 8, 4:22 PMsignalseverity 0.17

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

55. ?Sep 8, 1:24 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] IDXX is down 13.4% from its 30-day high with no headline news, no insider selling, no fundamental deterioration visible in the sparse 10-Q/8-K filings, and no imminent earnings (61 days away). The Health Care sector ranks 2nd of 11 by 30-day relative strength with strong +5.32pt outperformance vs. SPY, suggesting the drop is somewhat idiosyncratic to IDXX rather than sector-wide. Options flow is modestly bullish with a P/C ratio of 0.88 and call volume slightly exceeding puts, though z-scores are unavailable. Net signal score is approximately 0 to +1: positives include clean earnings runway (+1) and neutral-to-improving macro/VIX at 30th percentile (+1); negatives include idiosyncratic drop in an outperforming sector (-1) and high 10Y yield at 4.75% which is a headwind for a premium-valued growth name like IDXX (-1). Anchoring at the ~55% base rate for a sound large-cap dip and adjusting marginally downward for idiosyncratic risk and rate headwinds yields a modest buy signal.

56. ?Sep 8, 1:24 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

57. !Sep 8, 1:24 PMsignalseverity 0.15

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

58. ?Sep 8, 11:25 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

59. !Sep 8, 11:25 AMsignalseverity 0.16

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

60. ?Sep 8, 11:25 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] IDXX is down 13.4% from its 30-day high with no headline news, no insider selling, no fundamental deterioration visible in the sparse 10-Q/8-K filings, and no imminent earnings (61 days away). The Health Care sector ranks 2nd of 11 by 30-day relative strength with strong +5.32pt outperformance vs. SPY, suggesting the drop is somewhat idiosyncratic to IDXX rather than sector-wide. Options flow is modestly bullish with a P/C ratio of 0.88 and call volume slightly exceeding puts, though z-scores are unavailable. Net signal score is approximately 0 to +1: positives include clean earnings runway (+1) and neutral-to-improving macro/VIX at 30th percentile (+1); negatives include idiosyncratic drop in an outperforming sector (-1) and high 10Y yield at 4.75% which is a headwind for a premium-valued growth name like IDXX (-1). Anchoring at the ~55% base rate for a sound large-cap dip and adjusting marginally downward for idiosyncratic risk and rate headwinds yields a modest buy signal.

61. ?Sep 4, 4:24 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] IDXX is down 13.4% from its 30-day high with no headline news, no insider selling, no fundamental deterioration visible in the sparse 10-Q/8-K filings, and no imminent earnings (61 days away). The Health Care sector ranks 2nd of 11 by 30-day relative strength with strong +5.32pt outperformance vs. SPY, suggesting the drop is somewhat idiosyncratic to IDXX rather than sector-wide. Options flow is modestly bullish with a P/C ratio of 0.88 and call volume slightly exceeding puts, though z-scores are unavailable. Net signal score is approximately 0 to +1: positives include clean earnings runway (+1) and neutral-to-improving macro/VIX at 30th percentile (+1); negatives include idiosyncratic drop in an outperforming sector (-1) and high 10Y yield at 4.75% which is a headwind for a premium-valued growth name like IDXX (-1). Anchoring at the ~55% base rate for a sound large-cap dip and adjusting marginally downward for idiosyncratic risk and rate headwinds yields a modest buy signal.

62. ?Sep 4, 4:23 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

63. !Sep 4, 4:23 PMsignalseverity 0.14

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

64. ?Sep 4, 2:25 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] IDXX is down 13.4% from its 30-day high with no headline news, no insider selling, no fundamental deterioration visible in the sparse 10-Q/8-K filings, and no imminent earnings (61 days away). The Health Care sector ranks 2nd of 11 by 30-day relative strength with strong +5.32pt outperformance vs. SPY, suggesting the drop is somewhat idiosyncratic to IDXX rather than sector-wide. Options flow is modestly bullish with a P/C ratio of 0.88 and call volume slightly exceeding puts, though z-scores are unavailable. Net signal score is approximately 0 to +1: positives include clean earnings runway (+1) and neutral-to-improving macro/VIX at 30th percentile (+1); negatives include idiosyncratic drop in an outperforming sector (-1) and high 10Y yield at 4.75% which is a headwind for a premium-valued growth name like IDXX (-1). Anchoring at the ~55% base rate for a sound large-cap dip and adjusting marginally downward for idiosyncratic risk and rate headwinds yields a modest buy signal.

65. ?Sep 4, 2:24 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

66. !Sep 4, 2:24 PMsignalseverity 0.14

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

67. ?Sep 4, 1:25 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] IDXX is down 13.4% from its 30-day high with no headline news, no insider selling, no fundamental deterioration visible in the sparse 10-Q/8-K filings, and no imminent earnings (61 days away). The Health Care sector ranks 2nd of 11 by 30-day relative strength with strong +5.32pt outperformance vs. SPY, suggesting the drop is somewhat idiosyncratic to IDXX rather than sector-wide. Options flow is modestly bullish with a P/C ratio of 0.88 and call volume slightly exceeding puts, though z-scores are unavailable. Net signal score is approximately 0 to +1: positives include clean earnings runway (+1) and neutral-to-improving macro/VIX at 30th percentile (+1); negatives include idiosyncratic drop in an outperforming sector (-1) and high 10Y yield at 4.75% which is a headwind for a premium-valued growth name like IDXX (-1). Anchoring at the ~55% base rate for a sound large-cap dip and adjusting marginally downward for idiosyncratic risk and rate headwinds yields a modest buy signal.

68. ?Sep 4, 1:24 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

69. !Sep 4, 1:24 PMsignalseverity 0.14

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

70. ?Sep 4, 12:24 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] IDXX is down 13.4% from its 30-day high with no headline news, no insider selling, no fundamental deterioration visible in the sparse 10-Q/8-K filings, and no imminent earnings (61 days away). The Health Care sector ranks 2nd of 11 by 30-day relative strength with strong +5.32pt outperformance vs. SPY, suggesting the drop is somewhat idiosyncratic to IDXX rather than sector-wide. Options flow is modestly bullish with a P/C ratio of 0.88 and call volume slightly exceeding puts, though z-scores are unavailable. Net signal score is approximately 0 to +1: positives include clean earnings runway (+1) and neutral-to-improving macro/VIX at 30th percentile (+1); negatives include idiosyncratic drop in an outperforming sector (-1) and high 10Y yield at 4.75% which is a headwind for a premium-valued growth name like IDXX (-1). Anchoring at the ~55% base rate for a sound large-cap dip and adjusting marginally downward for idiosyncratic risk and rate headwinds yields a modest buy signal.

71. ?Sep 4, 12:24 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

72. !Sep 4, 12:24 PMsignalseverity 0.15

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

73. ?Sep 3, 4:22 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

74. !Sep 3, 4:22 PMsignalseverity 0.15

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

75. ?Sep 3, 4:22 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] IDXX is down 13.4% from its 30-day high with no headline news, no insider selling, no fundamental deterioration visible in the sparse 10-Q/8-K filings, and no imminent earnings (61 days away). The Health Care sector ranks 2nd of 11 by 30-day relative strength with strong +5.32pt outperformance vs. SPY, suggesting the drop is somewhat idiosyncratic to IDXX rather than sector-wide. Options flow is modestly bullish with a P/C ratio of 0.88 and call volume slightly exceeding puts, though z-scores are unavailable. Net signal score is approximately 0 to +1: positives include clean earnings runway (+1) and neutral-to-improving macro/VIX at 30th percentile (+1); negatives include idiosyncratic drop in an outperforming sector (-1) and high 10Y yield at 4.75% which is a headwind for a premium-valued growth name like IDXX (-1). Anchoring at the ~55% base rate for a sound large-cap dip and adjusting marginally downward for idiosyncratic risk and rate headwinds yields a modest buy signal.

76. ?Sep 3, 3:23 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] IDXX is down 13.4% from its 30-day high with no headline news, no insider selling, no fundamental deterioration visible in the sparse 10-Q/8-K filings, and no imminent earnings (61 days away). The Health Care sector ranks 2nd of 11 by 30-day relative strength with strong +5.32pt outperformance vs. SPY, suggesting the drop is somewhat idiosyncratic to IDXX rather than sector-wide. Options flow is modestly bullish with a P/C ratio of 0.88 and call volume slightly exceeding puts, though z-scores are unavailable. Net signal score is approximately 0 to +1: positives include clean earnings runway (+1) and neutral-to-improving macro/VIX at 30th percentile (+1); negatives include idiosyncratic drop in an outperforming sector (-1) and high 10Y yield at 4.75% which is a headwind for a premium-valued growth name like IDXX (-1). Anchoring at the ~55% base rate for a sound large-cap dip and adjusting marginally downward for idiosyncratic risk and rate headwinds yields a modest buy signal.

77. ?Sep 3, 3:22 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

78. !Sep 3, 3:22 PMsignalseverity 0.15

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

79. ?Sep 3, 1:23 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

80. !Sep 3, 1:23 PMsignalseverity 0.15

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

81. ?Sep 3, 1:23 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] IDXX is down 13.4% from its 30-day high with no headline news, no insider selling, no fundamental deterioration visible in the sparse 10-Q/8-K filings, and no imminent earnings (61 days away). The Health Care sector ranks 2nd of 11 by 30-day relative strength with strong +5.32pt outperformance vs. SPY, suggesting the drop is somewhat idiosyncratic to IDXX rather than sector-wide. Options flow is modestly bullish with a P/C ratio of 0.88 and call volume slightly exceeding puts, though z-scores are unavailable. Net signal score is approximately 0 to +1: positives include clean earnings runway (+1) and neutral-to-improving macro/VIX at 30th percentile (+1); negatives include idiosyncratic drop in an outperforming sector (-1) and high 10Y yield at 4.75% which is a headwind for a premium-valued growth name like IDXX (-1). Anchoring at the ~55% base rate for a sound large-cap dip and adjusting marginally downward for idiosyncratic risk and rate headwinds yields a modest buy signal.

82. ?Sep 3, 11:26 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] IDXX is down 13.4% from its 30-day high with no headline news, no insider selling, no fundamental deterioration visible in the sparse 10-Q/8-K filings, and no imminent earnings (61 days away). The Health Care sector ranks 2nd of 11 by 30-day relative strength with strong +5.32pt outperformance vs. SPY, suggesting the drop is somewhat idiosyncratic to IDXX rather than sector-wide. Options flow is modestly bullish with a P/C ratio of 0.88 and call volume slightly exceeding puts, though z-scores are unavailable. Net signal score is approximately 0 to +1: positives include clean earnings runway (+1) and neutral-to-improving macro/VIX at 30th percentile (+1); negatives include idiosyncratic drop in an outperforming sector (-1) and high 10Y yield at 4.75% which is a headwind for a premium-valued growth name like IDXX (-1). Anchoring at the ~55% base rate for a sound large-cap dip and adjusting marginally downward for idiosyncratic risk and rate headwinds yields a modest buy signal.

83. ?Sep 3, 11:25 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

84. !Sep 3, 11:25 AMsignalseverity 0.15

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

85. ❖Sep 3, 5:50 AMnewsvia finnhub

    Baron Focused Growth Fund Q2 2026 Portfolio Update

    The Fund's weightings are significantly different than those of the Benchmark, which explains why the Fund has such high active share of almost 100%. Read more here.

86. ?Sep 2, 4:23 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] IDXX is down 13.4% from its 30-day high with no headline news, no insider selling, no fundamental deterioration visible in the sparse 10-Q/8-K filings, and no imminent earnings (61 days away). The Health Care sector ranks 2nd of 11 by 30-day relative strength with strong +5.32pt outperformance vs. SPY, suggesting the drop is somewhat idiosyncratic to IDXX rather than sector-wide. Options flow is modestly bullish with a P/C ratio of 0.88 and call volume slightly exceeding puts, though z-scores are unavailable. Net signal score is approximately 0 to +1: positives include clean earnings runway (+1) and neutral-to-improving macro/VIX at 30th percentile (+1); negatives include idiosyncratic drop in an outperforming sector (-1) and high 10Y yield at 4.75% which is a headwind for a premium-valued growth name like IDXX (-1). Anchoring at the ~55% base rate for a sound large-cap dip and adjusting marginally downward for idiosyncratic risk and rate headwinds yields a modest buy signal.

87. ?Sep 2, 4:23 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

88. !Sep 2, 4:23 PMsignalseverity 0.14

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

89. !Sep 2, 3:24 PMsignalseverity 0.13

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

90. !Sep 2, 10:26 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    IDXX is up 1.55% today, a moderate but meaningful move suggesting real buying flow. With 319 minutes remaining (essentially a full trading day still ahead), there is ample time for continuation. However, several factors temper confidence: (1) The move is only 1.55%, below the 2-5% threshold that signals strong conviction/large institutional flow, so it's more of a mild drift than a powerful momentum setup. (2) No news catalyst is present to explain or sustain the move — while absence of news is not disqualifying, it leaves the driver ambiguous (could be broad market lift or sector rotation rather than IDXX-specific conviction). (3) The macro context shows 5-year forward inflation expectations elevated at 1.7σ above trend, which creates a modestly unfavorable backdrop for rate-sensitive sectors — IDXX as a premium-priced healthcare/veterinary diagnostics name with high P/E is somewhat rate-sensitive to discount rate assumptions, creating a mild headwind. (4) No reversal signal is evident, which keeps direction as 'up' rather than flagging a fade. On balance, the momentum is mild, the macro is a slight negative, but time is ample and there is no reversal signal. This lands as a borderline continuation read just above the 0.5 threshold.

91. !Sep 2, 7:06 AMsignalseverity 0.13

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

92. !Sep 1, 4:23 PMsignalseverity 0.13

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    IDXX (IDEXX Laboratories) is a high-quality veterinary diagnostics company with historically strong fundamentals — recurring revenue from consumables, wide moats, and consistent earnings growth. The 10.9% dip from its 30-day high is moderate and not explained by any confirmed negative catalyst (no headlines, no alarming SEC disclosures, no insider selling). However, evidence supporting a rebound is also thin: no insider cluster buys, no unusual call flow, no analyst upgrades, and no clear identifiable catalyst before the next earnings in 70 days. The macro backdrop shows elevated 10Y yields (4.65%) which are a structural headwind for high-multiple health care names like IDXX, and the 5-year inflation forward is running 1.8σ above trend — adding pressure on rate-sensitive equities. Health Care sector is mid-ranked (4 of 11) with slight recent underperformance vs SPY over 30 days, suggesting the dip may be partly sector-driven with no clear near-term recovery catalyst.

93. ❖Aug 31, 3:00 PMnewsvia finnhub

    IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference

    WESTBROOK, Maine, August 31, 2026--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, from 10:45 am – 11:20 am (ET).

94. ❖Aug 30, 4:10 PMnewsvia finnhub

    Tracking Terry Smith's Fundsmith 13F Portfolio - Q2 2026 Update

    Fundsmith's 13F portfolio rose to ~$13.65B in Q2 2026, expanding holdings from 34 to 41. Click here to read more about the portfolio.

95. ▢Aug 26, 8:00 PMjournal

    Agent 4 — Dip Buyer (Frozen) opened long 1 @ $553.44

96. ❖Aug 25, 7:01 AMnewsvia finnhub

    Insider Decision: Andrew Emerson Exercises Options At IDEXX Laboratories For $101K

    In a new SEC filing on August 24, it was revealed that Emerson, EVP at IDEXX Laboratories (NASDAQ:IDXX), executed a significant exercise of company stock options. What Happened: A Form 4 filing with the U.S. Securities

97. ▣Aug 23, 8:00 PMjournaltime_stop

    Agent 5 — Dip Buyer (Evolving) closed long 3 @ $556.34 (-$1.60)

    Time stop: held 101 ≥ 90 days

98. ❖Aug 8, 4:00 AMnewsvia finnhub

    IDEXX Laboratories: Worth The Premium

    IDEXX Labs remains a buy: durable moat, recurring revenue, raised FY26 EPS outlook, and long-term international growth. Click to see Q2 highlights & valuation.

99. ❖Aug 6, 12:45 PMnewsvia finnhub

    Here is Why Growth Investors Should Buy Idexx (IDXX) Now

    Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.

100. ❖Aug 5, 12:27 PMnewsvia finnhub

     UBS Maintains Neutral on IDEXX Laboratories, Raises Price Target to $670

     UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and raises the price target from $620 to $670.

101. ❖Aug 5, 10:58 AMnewsvia finnhub

     Citigroup Maintains Neutral on IDEXX Laboratories, Raises Price Target to $670

     Citigroup analyst Daniel Grosslight maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and raises the price target from $650 to $670.

102. ❖Aug 4, 6:15 PMnewsvia finnhub

     IDEXX Laboratories, Inc. Q2 2026 Earnings Call Summary

     Moby summary of IDEXX Laboratories, Inc.'s Q2 2026 earnings call

103. ❖Aug 4, 5:04 PMnewsvia finnhub

     IDEXX Laboratories Inc (IDXX) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and ...

     IDEXX Laboratories Inc (IDXX) delivers 10% revenue growth and raises full-year EPS outlook, driven by innovation and international expansion despite soft US clinical visits.

104. ❖Aug 4, 12:04 PMnewsvia finnhub

     IDEXX Laboratories Q2 Earnings Call Highlights

     IDEXX Laboratories (NASDAQ:IDXX) reported second-quarter 2026 revenue growth of approximately 10% on a reported basis and 9% organically, driven by companion animal diagnostics, water and livestock, poultry and dairy businesses. The company raised its full-year revenue and earnings outlook, citing s

105. ❖Aug 4, 11:50 AMnewsvia finnhub

     IDXX Q2 Earnings & Revenues Beat, '26 EPS View Up, Stock Up in Pre-Market

     IDEXX Laboratories beats Q2 estimates, expands margins and raises its 2026 EPS outlook as diagnostics demand and adoption fuel growth.

106. ❖Aug 4, 9:30 AMnewsvia finnhub

     Idexx (IDXX) Reports Q2 Earnings: What Key Metrics Have to Say

     The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

107. ❖Aug 4, 9:14 AMnewsvia finnhub

     Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Amid Strait of Hormuz Re-Opening Hopes

     The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.3% and the actively trad

108. ❖Aug 4, 8:40 AMnewsvia finnhub

     IDEXX Laboratories, Inc. (IDXX) Q2 2026 Earnings Call Transcript

     IDEXX Laboratories, Inc. (IDXX) Q2 2026 Earnings Call August 4, 2026 8:30 AM EDTCompany ParticipantsAndrew Emerson - Executive VP, CFO &...

109. ❖Aug 4, 8:30 AMnewsvia finnhub

     SR Inc Net Zero Consortium for Buyers: Seven-Buyer Aggregation for 180 MW of Millers Branch Solar Now Online

     The 180 MW Phase II portion of the Millers Branch Solar Facility in Haskell County, Texas has achieved commercial operation. The capacity was contracted through Sustainability Roundtable, Inc's Net Zero Consortium for Buyers (NZCB) by Cisco, Juniper Networks (now part of Hewlett Packard Enterprise), Bio-Rad Laboratories, Cadence Design Systems, IDEXX Laboratories, Inc., PTC, and a large healthcare company, which signed an aggregated virtual power purchase agreement (VPPA) with Southern Power Com

110. ❖Aug 4, 8:15 AMnewsvia finnhub

     IDEXX Laboratories Shares Climb After Earnings Beat and Improved Full-Year Outlook

     IDEXX Laboratories Inc. (NASDAQ:IDXX) shares rose nearly 4% in pre-market trading after the veterinary diagnostics company reported second-quarter 2026 results that exceeded Wall Street expectations and increased its full-year earnings guidance.

111. ❖Aug 4, 7:40 AMnewsvia finnhub

     Idexx Laboratories (IDXX) Q2 Earnings and Revenues Top Estimates

     Idexx (IDXX) delivered earnings and revenue surprises of +8.10% and +1.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

112. ❖Aug 4, 7:39 AMnewsvia finnhub

     Why Is IDEXX Laboratories Stock Gaining Tuesday?

     IDEXX Laboratories (IDXX) stock rose after reporting Q2 earnings of $4.27/share and $1.22B in revenue, beating Wall Street estimates.

113. ❖Aug 4, 7:38 AMnewsvia finnhub

     IDEXX Laboratories (NASDAQ:IDXX) Shares Rise on Q2 Earnings Beat and Improved Outlook

     IDEXX Laboratories Q2 EPS beats estimates, revenue in line; raises full-year organic growth and margin outlook, shares rise 3.7% premarket.

114. ❖Aug 4, 6:30 AMnewsvia finnhub

     IDEXX Laboratories Announces Second Quarter Results

     WESTBROOK, Maine, August 04, 2026--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced second quarter results.

115. ❖Aug 4, 5:35 AMnewsvia finnhub

     IDEXX Laboratories Q2 2026 Earnings Call Transcript

     IDEXX Laboratories (NASDAQ:IDXX) reported second-quarter financial results on Tuesday. The transcript from the company&#39;s second-quarter earnings call has been provided below. This transcript is brought to you by

116. ❖Aug 4, 2:31 AMnewsvia finnhub

     IDEXX Laboratories Raises FY2026 GAAP EPS Guidance from $14.45-$14.90 to $14.69-$14.94 vs $14.67 Est; Narrows FY2026 Sales Guidance from $4.675B-$4.760B to $4.700B-$4.745B vs $4.711B Est

     IDEXX Laboratories (NASDAQ:IDXX) raises FY2026 GAAP EPS guidance from $14.45-$14.90 to $14.69-$14.94 vs $14.67 analyst estimate. Narrows FY2026 sales outlook from $4.675 billion-$4.760 billion to $4.700 billion-$4.745

117. ❖Aug 4, 2:30 AMnewsvia finnhub

     IDEXX Laboratories Q2 EPS $4.27 Beats $3.96 Estimate, Sales $1.217B Beat $1.201B Estimate

     IDEXX Laboratories (NASDAQ:IDXX) reported quarterly earnings of $4.27 per share which beat the analyst consensus estimate of $3.96 by 7.83 percent. This is a 17.63 percent increase over earnings of $3.63 per share from

118. ▣Aug 3, 8:00 PMjournalstop

     Agent 9 — Bear Equity closed short 18 @ $614.18 (-$1,463.76)

     intraday stop sweep

119. ❖Jul 30, 5:09 AMnewsvia finnhub

     Is IDEXX Laboratories (IDXX) Fairly Valued After Its 2025 Corporate Responsibility Report?

     Corporate responsibility report puts IDEXX Laboratories (IDXX) in focus IDEXX Laboratories (IDXX) recently released its 2025 Corporate Responsibility Report, drawing attention to the stock as investors assess how the company’s plans for pet diagnostics, employees, and sustainability fit into its long term outlook. See our latest analysis for IDEXX Laboratories. The recent 6.3% 30 day share price return contrasts with IDEXX Laboratories’ share price being down 15.0% year to date, while the 3...

120. ❖Jul 28, 10:06 AMnewsvia finnhub

     IDEXX Releases 2025 Corporate Responsibility Report Highlighting Innovation and Sustainability Progress

     IDEXX Laboratories (NASDAQ:IDXX) released its 2025 Corporate Responsibility Report, outlining progress across innovation, workforce development, and environmental initiatives that support the company’s long-term growth strategy. Key Investor TakeawaysIDEXX published its 2025 Corporate Responsibility Report, highlighting advances in innovation, employee development, and sustainability.

121. ❖Jul 28, 7:00 AMnewsvia finnhub

     IDEXX Releases 2025 Corporate Responsibility Report, Highlighting Progress Against Its Goals

     WESTBROOK, Maine, July 28, 2026--IDEXX releases 2025 Corporate Responsibility Report highlighting progress against its goals and commitments.

122. ❖Jul 27, 1:09 PMnewsvia finnhub

     Elanco Seems Best-Positioned Into Q2 Print Among Animal Health Stocks, UBS Says

     Elanco Animal Health (ELAN) seems "best-positioned name" into the Q2 print, with IDEXX Laboratories

123. ❖Jul 27, 10:08 AMnewsvia finnhub

     UBS Maintains Neutral on IDEXX Laboratories, Lowers Price Target to $620

     UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and lowers the price target from $640 to $620.

124. ❖Jul 27, 9:11 AMnewsvia finnhub

     Here's How IDEXX Laboratories Is Placed Ahead of Q2 Earnings

     IDXX Laboratories heads into Q2 earnings with revenue and EPS growth expected, led by CAG diagnostics, VetLab gains and expanding software adoption.

125. ❖Jul 27, 8:00 AMnewsvia finnhub

     IDEXX Laboratories (IDXX) Looks Attractive on Recurring Revenue and High Customer Retention

     Jensen Investment Management, an asset management company based in the US, released its second-quarter 2026 investor letter for the “Jensen Quality Growth Equity Composite “. A copy of the letter is available to download here. The fund seeks long-term growth by investing in high-quality companies with durable competitive advantages. It returned 10.94% net of fees in […]

126. ▢Jul 26, 8:00 PMjournal

     Agent 7 — Day Trader opened long 5 @ $559.56

127. ▣Jul 26, 8:00 PMjournaltime_stop

     Agent 7 — Day Trader closed long 5 @ $555.52 (-$20.20)

     EOD forced close — day trader never carries overnight

128. ❖Jul 19, 9:43 AMnewsvia finnhub

     Tracking Ron Baron's BAMCO Portfolio - Q1 2026 Update

     Ron Baron’s BAMCO 13F update: $33.13B portfolio with Tesla top stake (13.39%), major buys/sells, and rebalancing moves—read more now.

129. ❖Jul 17, 9:00 PMnewsvia finnhub

     Fat cat? Weight-loss drugs may be coming for your overweight pet

     Startups are testing GLP-1 treatments for overweight cats while pet-food giants are leaning into longevity products as owners spend more on animal health.

130. ❖Jul 15, 3:05 PMnewsvia finnhub

     Which S&P500 stocks are moving on Wednesday?

     Curious about the S&P500 stocks that are in motion on Wednesday? Join us as we explore the top movers within the S&P500 index during today's session.

131. ❖Jul 15, 12:35 PMnewsvia finnhub

     These S&P500 stocks are moving in today's session

     Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

132. ❖Jul 14, 10:45 AMnewsvia finnhub

     These 3 Water ETFs Could be Quiet Winners From Infrastructure Spending

     As data centers strain water systems, FIW, PHO, and CGW offer investors ETF-based access to water utilities, infrastructure, and equipment firms, each with distinct fees and concentration.

133. ❖Jul 14, 7:37 AMnewsvia finnhub

     Buy 3 AI-Led Medical Devices Laggards of 1H Set to Gather Pace in 2H

     ISRG, IDXX and ALC are three AI-driven medical device laggards with strong business momentum and improving earnings estimates for a potential 2H rebound.

134. ❖Jul 13, 10:00 AMnewsvia finnhub

     IDEXX Laboratories Earnings Preview: What to Expect

     IDEXX Laboratories will release its second-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.

135. ❖Jul 9, 10:28 AMnewsvia finnhub

     Illumina Stock Gains 43.7% in 2026: What's Powering the Rally?

     ILMN stock's 43.7% 2026 rally is fueled by strong sequencing demand, NovaSeq X momentum and progress toward higher growth and profitability.

136. ❖Jul 9, 8:00 AMnewsvia finnhub

     National Veterinary Associates Welcomes Laura Tortorella and Tina Hunt, PhD, to Board of Directors

     National Veterinary Associates (NVA), a leading pet healthcare services company, today announced the appointment of Laura Tortorella, Chief Executive Officer of AccentCare, and Tina Hunt, PhD, former Executive Vice President of IDEXX Laboratories, to its Board, effective immediately.

137. ❖Jul 7, 11:40 AMnewsvia finnhub

     ALC vs. IDXX: Which Stock Is the Better Value Option?

     ALC vs. IDXX: Which Stock Is the Better Value Option?

138. ❖Jul 7, 3:58 AMnewsvia finnhub

     IDEXX Laboratories Does Not Need More Vet Visits--But It Needs More Tests Per Visit

     IDEXX Laboratories (IDXX) is rated Hold, as its premium valuation (~38x 2026E EPS) already assumes strong recurring revenue and diagnostics growth.

139. ❖Jul 1, 4:00 PMnewsvia finnhub

     IDEXX Laboratories to Release 2026 Second Quarter Financial Results

     WESTBROOK, Maine, July 01, 2026--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 second quarter financial results for Tuesday, August 4, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.

140. ▢May 14, 8:00 PMjournal

     Agent 9 — Bear Equity opened short 18 @ $532.86

141. ▢May 14, 8:00 PMjournal

     Agent 5 — Dip Buyer (Evolving) opened long 3 @ $556.87